Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03799601 | Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC(ALTER-L013) | unknown | Phase 4 | 45 | Tongji HospitalOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT03791151 | Pharmacogenetics in Non Small Cell Lung Cancer | unknown | — | 100 | Ain Shams UniversityOTHER | 1 | Jan 2, 2019 | clinicaltrials |
| NCT03565120 | Aggressive Thoracic Radiotherapy for Stage Ⅳ Non Small Cell Lung Cancer | unknown | N/A | 60 | yu gengshengOTHER | 1 | Dec 26, 2018 | clinicaltrials |
| NCT03432156 | Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 68 | Beijing Friendship HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03771404 | NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy" | unknown | N/A | 50 | Hellenic Oncology Research GroupOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT03765775 | Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative | unknown | Phase 2 | 20 | First Hospital of Shijiazhuang CityOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT03732001 | A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC(ALTER-L024) | unknown | Phase 2 | 80 | China Medical University, ChinaOTHER | 1 | Nov 28, 2018 | clinicaltrials |
| NCT03754530 | Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation | unknown | Phase 2 | 162 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT03750916 | Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer(ACDFNSNSCLC) | unknown | Phase 2 | 46 | Qilu Hospital of Shandong UniversityOTHER | 0 | Nov 26, 2018 | clinicaltrials |
| NCT03517332 | Circulating Tumor DNA Exposure in Peripheral Blood | unknown | — | 10,000 | Quantgene Inc.INDUSTRY | 2 | Nov 20, 2018 | clinicaltrials |
| NCT03664843 | Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients | unknown | — | 120 | First Hospital of Shijiazhuang CityOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT03735264 | Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）(ACDFNSCLC) | unknown | Phase 2 | 46 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Nov 8, 2018 | clinicaltrials |
| NCT03728374 | Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma | unknown | Phase 2 | 38 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Nov 2, 2018 | clinicaltrials |
| NCT03725423 | Apatinib for Advanced Lung Squmamous Carcinoma | unknown | Phase 4 | 50 | Xuzhou Central HospitalOTHER | 0 | Oct 31, 2018 | clinicaltrials |
| NCT01788332 | Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)(PIN) | unknown | Phase 2 | 70 | Lisette NixonOTHER_GOV | 1 | Oct 26, 2018 | clinicaltrials |
| NCT03710629 | A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes | unknown | — | 750 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT03700333 | Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC | unknown | Phase 3 | 120 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Oct 9, 2018 | clinicaltrials |
| NCT03692442 | Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform | unknown | — | 80 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT03680183 | Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV) | unknown | — | 300 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT02811354 | Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA(PLASMA) | unknown | Phase 2 | 108 | National University Hospital, SingaporeOTHER | 5 | Sep 20, 2018 | clinicaltrials |
| NCT03671538 | Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin | unknown | N/A | 62 | Lingyu LuoOTHER | 0 | Sep 17, 2018 | clinicaltrials |
| NCT03672136 | Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients | unknown | Phase 2 | 25 | Shandong Cancer Hospital and InstituteOTHER | 1 | Sep 14, 2018 | clinicaltrials |
| NCT03407300 | A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients | unknown | Phase 2 | 80 | Haining Health-Coming Biotech Co., Ltd.OTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT01407822 | Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer(EMERGING) | unknown | Phase 2 / Phase 3 | 72 | Guangdong Association of Clinical TrialsOTHER | 1 | Sep 11, 2018 | clinicaltrials |
| NCT03108560 | Sublobar Resection Versus Lobectomy for cT1N0M0 Non-small-cell Lung Cancer | unknown | N/A | 600 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT03509779 | Pronostic and Predictive Value of EMT in Localized Lung Cancer(TWISTlung) | unknown | — | 1,000 | European Georges Pompidou HospitalOTHER | 1 | Sep 6, 2018 | clinicaltrials |
| NCT01669707 | Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 60 | Beijing Chest HospitalOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT03656393 | To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma(RCTACSCNSCLC) | unknown | Phase 3 | 48 | Shenzhen People's HospitalOTHER | 1 | Sep 4, 2018 | clinicaltrials |
| NCT03654027 | Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC | unknown | Phase 2 | 84 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 0 | Aug 31, 2018 | clinicaltrials |
| NCT02450656 | Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer(M14AFS) | unknown | Phase 1 / Phase 2 | 320 | The Netherlands Cancer InstituteOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT03636685 | Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | unknown | Phase 1 / Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 17, 2018 | clinicaltrials |
| NCT03480230 | Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | unknown | Phase 2 | 60 | Arafat TfayliOTHER | 2 | Aug 14, 2018 | clinicaltrials |
| NCT03616691 | Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC | unknown | Phase 2 | 46 | Samsung Medical CenterOTHER | 0 | Aug 6, 2018 | clinicaltrials |
| NCT03614065 | Endostar Combine With Radiotherapy in Brain Metastasis of NSCLC | unknown | Phase 2 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 3, 2018 | clinicaltrials |
| NCT03601598 | A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC | unknown | Phase 1 / Phase 2 | 41 | Harbin Medical UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT03602027 | Phase I Study of the Combination of Anlotinib With Gefitinib | unknown | N/A | 9 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT02507518 | Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer(CALMETTE) | unknown | Phase 2 | 80 | Centre Henri BecquerelOTHER | 1 | Jul 23, 2018 | clinicaltrials |
| NCT03594682 | Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study | unknown | N/A | 31 | Beijing Chest HospitalOTHER | 0 | Jul 20, 2018 | clinicaltrials |
| NCT03396185 | Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer | unknown | Phase 2 | 30 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 18, 2018 | clinicaltrials |
| NCT02433574 | Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection(LINNEARRE-I) | unknown | N/A | 20 | Juravinski Cancer CenterOTHER | 1 | Jul 17, 2018 | clinicaltrials |
| NCT03583723 | Adaptive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (LARTIA Trial)(LARTIA) | unknown | N/A | 50 | Campus Bio-Medico UniversityOTHER | 1 | Jul 12, 2018 | clinicaltrials |
| NCT02980536 | cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China | unknown | — | 129 | Berry Genomics Co., Ltd.INDUSTRY | 1 | Jul 11, 2018 | clinicaltrials |
| NCT02655536 | Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial(BRILLIANT) | unknown | Phase 2 | 109 | National Taiwan University HospitalOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT03533127 | A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer | unknown | Phase 3 | 648 | Luye Pharma Group Ltd.INDUSTRY | 1 | Jul 10, 2018 | clinicaltrials |
| NCT03566576 | Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel | unknown | N/A | 18 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 25, 2018 | clinicaltrials |
| NCT03546452 | A Prospective Study to Evaluate the Consistency of Next-Generation Sequencing(NGS)-Panels by Using Malignant Hydrothorax Form NSCLC | unknown | — | 50 | Shanghai Chest HospitalOTHER | 1 | Jun 7, 2018 | clinicaltrials |
| NCT02956551 | Personalized DC Vaccine for Lung Cancer(SKLB1608) | unknown | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | May 31, 2018 | clinicaltrials |
| NCT03527251 | Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC(SEQUENCE) | unknown | Phase 1 | 10 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT02696525 | Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients | unknown | — | 145 | Peking University People's HospitalOTHER | 1 | May 21, 2018 | clinicaltrials |
| NCT03525782 | Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC | unknown | Phase 1 / Phase 2 | 60 | The First Affiliated Hospital of Guangdong Pharmaceutical UniversityOTHER | 1 | May 16, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Jan 10, 2019source: clinicaltrials